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A B S T R A C T
Background. Changes in recipient and donor factors have
reopened the question of survival benefits of kidney transplan-
tation versus dialysis.
Methods. We analysed survival among 3808 adult Belgian
patients waitlisted for a first deceased donor kidney transplant
from 2000 to 2012. The primary outcome was mortality during
the median waiting time plus 3 years of follow-up after trans-
plantation or with continued dialysis. Outcomes were analysed
separately for standard criteria donor (SCD) and expanded cri-
teria donor (ECD) kidney transplants. We adjusted survival
analyses for recipient age (20–44, 45–64 and 65 years), sex
and diabetes as the primary renal disease.
Results. Among patients65 years of age, only SCD transplan-
tation provided a significant survival benefit compared with
dialysis, with a mortality of 16.3% [95% confidence interval (CI)
13.2–19.9] with SCD transplantation, 20.5% (95% CI 16.1–24.6)
with ECD transplantation and 24.6% (95% CI 19.4–29.5) with
continued dialysis. Relative mortality risk was increased in the
first months after transplantation compared with dialysis, with
equivalent risk levels reached earlier with SCD than ECD trans-
plantation in all age groups.
Conclusions. The results of this study suggest that older
patients might gain a survival benefit with SCD transplantation
versus dialysis, but any survival benefit with ECD transplanta-
tion versus dialysis may be small.
Keywords: dialysis, elderly, expanded criteria donor, kidney
transplantation, survival
I N T R O D U C T I O N
Since 1999, when Wolfe et al. [1] reported a survival benefit
for US patients receiving a first deceased donor kidney trans-
plantation as compared with waitlisted dialysis patients, kidney
transplantation has been assumed to offer better survival.
The results of that study motivated the choice of kidney trans-
plantation for end-stage renal disease (ESRD), even for older
patients. However, in that study only 15% (n¼ 6925) of the
total study population was 60 years of age at the time of
waitlisting, suggesting the possibility of a selection bias toward
fit older patients being considered eligible for transplantation.
In the ensuing two decades, the kidney transplantation
landscape has evolved profoundly. First, the median age of
recipients of a deceased donor kidney increased from 45 years
in 1990 to 56 years in 2016, according to Eurotransplant, an or-
gan allocation organization that allocates deceased donor
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What was already known about this subject?
• Older studies have shown a survival benefit with kidney transplantation compared with dialysis, even for patients
>60 years of age. However, due to important evolutions such as older recipient age and the use of less-than-optimal-
quality donors, it is unclear if the survival benefit with transplantation still holds true today.
What this study adds?
• Among patients 65 years of age waitlisted for a first deceased donor kidney transplant in Belgium, only standard
criteria donor (SCD) transplantation provided a significant survival benefit compared with continued dialysis.
• The relative risk of mortality in the first months after transplantation was higher with expanded criteria donor (ECD)
than with SCD transplantation.
• The results of this study suggest that older patients might gain a survival benefit with SCD transplantation versus
dialysis, but any survival benefit with ECD transplantation versus dialysis may be small.
What impact this may have on practice or policy?
• Older transplant candidates should be informed that any survival benefit with ECD transplantation may be small.
• The acceptance of an ECD transplant should be carefully balanced against the risks of continued dialysis while waiting
for a better donor offer.
• Larger European studies are needed to provide more precise estimates of the survival benefit with transplantation.
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organs in Austria, Belgium, Croatia, Germany, Hungary,
Luxembourg, The Netherlands and Slovenia [2]. Furthermore,
in keeping with this higher median age, current transplant
recipients are more likely to have more pretransplant
comorbidities [3]. Because of organ shortages, older-donor kid-
neys and donor kidneys of suboptimal quality are being trans-
planted. In Eurotransplant, the median age of deceased kidney
donors has risen steeply from 36 years in 1990 to 54 years in
2016 [2], and about one-third of them can now be classified as
expanded criteria donors (ECDs) [2, 4]. By definition, ECD kid-
neys show inferior graft survival compared with those from
standard criteria donors (SCDs), with a relative risk of graft fail-
ure of >1.7 [4]. Moreover, transplantation with an ECD com-
pared with an SCD kidney negatively affects patient survival
[5]. In parallel with these important changes in the transplanta-
tion field, improved management of chronic kidney disease and
dialysis care has led to improved survival on dialysis in Europe
and the USA [6, 7].
The result of these developments is a situation of more high-
risk transplantations (older candidates, more comorbidities)
with more donor kidneys of suboptimal quality even as survival
on dialysis is improving. Recent studies that update outcomes
with transplantation versus dialysis are quite limited, especially
for Europe, and show diverging results [8–11]. Development of
such studies is hampered because many countries lack a com-
prehensive registry that captures waitlist, transplantation and
outcome data such as patient and graft survival.
In this study we analysed patient survival data for adults (age
20 years) waitlisted for a first deceased donor kidney trans-
plantation in Belgium, a European country of 11 million inhabi-
tants. We divided the population into three age groups and
compared survival with either SCD or ECD transplantation ver-
sus continued dialysis. For this purpose we linked waitlist and
donor data from Eurotransplant with patient survival data for
Belgian ESRD patients from the two regional Belgian renal reg-
istries [Nederlandstalige Belgische Vereniging voor Nefrologie
(NBVN) and Groupement des Néphrologues Francophones de
Belgique (GNFB)] from the Dutch-speaking and French-
speaking part of Belgium, respectively.
M A T E R I A L S A N D M E T H O D S
Study population
The study population was selected from 5098 patients
20 years of age who were registered on the Eurotransplant
waitlist for a first kidney-only transplantation in Belgium be-
tween 1 January 2000 and 31 December 2012. The
Eurotransplant database contains complete data sets about wai-
tlisting and detailed donor data (mandatory data set), but sur-
vival data on transplant recipients are incomplete (not
mandatory). Therefore we needed to merge the selected study
population from the Eurotransplant database with data from
two Belgium renal registries (NBVN and GNFB) containing
follow-up data of patients on renal replacement therapy (e.g.
mortality). With the explicit consent of NBVN, GNFB and all
Belgian transplant centers for the use of these data, merging of
the databases was performed at Eurotransplant and only strictly
anonymized data were made available for the analysis. Starting
from the selected Eurotransplant dataset containing 5098
patients, we were able to find the corresponding patient in the
Belgian renal registry database in 4180 (82%) of the cases
(Figure 1). Merging was done according to a specifically
designed algorithm. To explore the reasons why some
Eurotransplant records could not be linked to data from the
Belgian registries, we previously performed a feasibility study
based on the Antwerp cohort (representing 10% of the wai-
tlisted population in Belgium); failed linking was due to data en-
try differences (e.g. spelling errors) between databases, patients
who were waitlisted in Belgium but received dialysis abroad,
patients on the waitlist but not yet on dialysis during the study
period, patients 20 years of age at waitlisting who were still
treated by paediatric nephrologists (who in Belgium do not reg-
ister patients in the national renal registries) or patients not cap-
tured in the national Belgian renal registries because of errors
(unpublished data). Of the original 4180 patients, 372 were ex-
cluded: 228 patients received a living donor transplantation, 68
patients never received active waitlist status after registration at
Eurotransplant and 76 had pre-emptive transplantations.
Therefore the final dataset for analysis contained 3808 patients.
Patient groups and definitions
Patients were followed from the moment they were both on
dialysis and actively waitlisted for a first deceased kidney donor
transplant. Patients who were transplanted during the study pe-
riod are referred to as ‘transplant recipients’, whereas those who
were not transplanted are referred to as ‘patients remaining on
dialysis’. Patients were divided into age categories (20–44,
45–64 and65 years) according to their age at the time of ac-
tive waitlisting while on dialysis. ECDs were defined as all
donors >60 years of age or donors >50 years meeting at least
any two of the following criteria: hypertension, cerebrovascular
cause of death or serum creatinine level >1.5 mg/dL before or-
gan recovery [4]. SCDs were donors who did not meet the ECD
criteria.
Outcomes
The main outcome was expressed as mortality probabilities.
For patients who received a kidney transplant, the mortality on
dialysis during the median waiting time for a kidney transplant
plus the mortality 3 years after transplantation was taken as the
primary outcome. For patients remaining on dialysis, the pri-
mary outcome was mortality during the median waiting time
plus mortality during the 3 years thereafter. Median waiting
time was defined as the time at which 50% of the waiting list
population was transplanted. Median waiting time plus 3 years
was chosen as the most appropriate length of follow-up because
of the small number of patients (<10%) remaining in the dialy-
sis subgroups after this period. For transplanted patients, out-
comes were also analysed separately for those receiving an ECD
or SCD kidney transplant.
Statistical analysis
Data on baseline characteristics are presented as medians
(25th–75th percentiles) or as percentages, unless otherwise
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specified. To compare the baseline characteristics of the differ-
ent study groups, we used chi-squared or non-parametric tests,
where applicable.
Simply beginning from waitlisting and then comparing mor-
tality probabilities between those who are eventually trans-
planted and those remaining on dialysis would result in
immortal time bias during the waiting time for the transplanted
group, as these patients will then, by definition, survive until the
day they receive a kidney transplantation. Therefore, calculation
of mortality probabilities for patients remaining on dialysis or
receiving a kidney transplant consisted of several steps. First, we
used the cumulative incidence competing risk method to calcu-
late the median waiting time for each of the age categories, from
the start of being actively waitlisted and on dialysis until trans-
plantation, with death or permanent delisting as competing
events. Second, we calculated mortality rates during the median
waiting time for each of the age categories using Cox regression.
For these analyses, the survival time started with the date of
active waitlisted dialysis and ended with the date of death or a
censored observation (delisting because of transplantation, re-
covery or loss to follow-up), the end of follow-up (median wait-
ing time per age category) or the end of the study period (31
December 2015). In these survival analyses, we did not censor
for delisting due to poor health status, because it is expected
that several patients who are delisted due to poor health may
die shortly thereafter, possibly in the study period. Therefore,
censoring for delisting due to poor health would have resulted
in an overestimation of survival. Models were adjusted for age
at active waitlisted dialysis, sex and diabetes as the cause of
ESRD. Analyses included the total group of patients and we
obtained age stratum–specific mortality rates by applying fixed
values for age (median age by each age category, i.e. 35.2 years
for age category 20–44, 55.2 years for age category 45–64
and 68.5 years for age category 65), sex (60%) and diabetes
(2%) to the Cox regression models. Third, for patients remain-
ing on dialysis, the adjusted mortality risk during the median
Adults (≥ 18 years old) waitlisted on the
Eurotransplant (ET) waiting list for a first
kidney-only transplant in Belgium between
1 January 2000 and 31 December 2012
(n=5098)
Excluded (N=918)
• Eurotransplant records that could
  not be linked with Belgian registry
  data
Excluded (N=372)
• Living donor transplants (N=228) 
• Never actively waitlisted (N=68) 
• Preemptive transplantations (N=76) 
Study population
(N=3808)





























Patients with linked data between
Eurotransplant and Belgian renal registries
(N=4180)
FIGURE 1: Study flowchart.
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waiting time was added to the adjusted mortality risk on dial-
ysis 3 years thereafter. This was calculated using the same
methods as described above, except that survival time was
extended to 3 years after the median waiting time. This
means that the analysis is based on the entire population
with censoring at the time of transplantation. Again, patients
were not censored at the time of delisting from the waiting
list due to poor health status. For patients who received a
kidney transplant during follow-up, the adjusted mortality
risk during the median waiting time was added to the ad-
justed mortality from transplantation until 3 years thereaf-
ter. For the calculation of the adjusted mortality from
transplantation until 3 years thereafter, survival time started
with the date of transplantation and ended with the date of
death, a censored observation (loss to follow-up), end of
follow-up (3 years after transplantation) or the end of the
study period (31 December 2015). Cox regression analysis
was used, again with adjustment for age at active waitlisted
dialysis, sex and diabetes as the cause of ESRD and using the
fixed values for age, sex and diabetes as described above. To
calculate the adjusted relative mortality risk after transplan-
tation versus the mortality of those remaining on dialysis
over time, we divided the monthly cumulative mortality
from transplantation by the cumulative mortality of those
still on dialysis from the median waiting time. Mortality
rates were adjusted for fixed values of age, sex and diabetes.
All statistical analyses were performed using SAS software
version 9.4 (SAS Institute, Cary, NC, USA).
R E S U L T S
Population characteristics
The final dataset for analysis contained 3808 patients.
Overall, 3341 of these patients initiated chronic dialysis treat-
ment before active waitlisting and 467 patients did so on the
day of or after active waitlisting. Patients were followed until
31 December 2015. The median follow-up time was 8.5 years
(25th–75th percentiles 5.5–12.4) in the 20–44-year age group,
7.4 years (25th–75th percentiles 4.5–10.5) in the 45–64-year age
group and 5.5 (25th–75th percentiles 3.5–8.5) in the 65-year
age group.
Of a total of 3808 waitlisted patients included in the study,
3382 (88.8%) underwent a kidney transplant during follow-up.
In the youngest age group of transplant recipients (20–44 years;
n¼ 919), 91% received an SCD kidney. In the 45–64-year age
group (n¼ 1964), 79% received an SCD kidney. In the oldest
age group (65 years; n¼ 499), 56% received an SCD kidney
(Figure 1).
Table 1 summarizes the baseline characteristics of the study
population. Transplant recipients were significantly younger
and more likely to have autosomal dominant polycystic kidney
disease or glomerulonephritis as causes of ESRD, whereas
those remaining on dialysis were older and more likely to have
ESRD caused by diabetes or hypertensive/vascular disease.
Recipients of ECD kidneys were older than SCD kidney recipi-
ents, more likely to have spent more time on dialysis before
active waitlisting and more likely to have ESRD caused by
Table 1. Baseline characteristics
Transplant recipients
Patient characteristics Total TX SCD ECD P-value** Waitlisted patients remaining
on dialysis (n¼ 426)
P-value*
(n¼ 3382) (n¼ 2666) (n¼ 716)
Agea (years), median (25–75th percentile) 53 (44–61) 51 (42–59) 61 (52–66) <0.001 56 (47–63) <0.001
Age distributiona, n (%)
20–44 919 (27) 840 (32) 79 (11) <0.001 87 (20) 0.003
45–64 1964 (58) 1548 (58) 416 (58) 0.986 249 (58) 0.881
65 499 (15) 278 (10) 221 (31) <0.001 90 (21) <0.001
Male, n (%) 2137 (63) 1694 (64) 443 (62) 0.411 256 (60) 0.213
Cause of renal failure, n (%)
ADPKD 626 (18) 494 (18) 132 (19) 0.954 57 (13) 0.009
Diabetes 60 (2) 48 (2) 12 (2) 0.823 25 (6) <0.001
Hypertension/vascular
disease
315 (9) 227 (9) 88 (12) 0.002 39 (9) 0.915
Glomerulonephritis 969 (29) 782 (29) 187 (26) 0.091 92 (22) 0.002
Uncertain aetiology 440 (13) 347 (13) 93 (13) 0.985 48 (11) 0.311
Other 972 (29) 768 (29) 204 (28) 0.868 165 (39) <0.001
Dialysis modalityb, n (%)
Haemodialysis 2151 (64) 1680 (63) 471 (66) 0.172 279 (65) 0.444
Peritoneal dialysis 669 (20) 525 (20) 144 (20) 0.802 76 (18) 0.341
No dialysis 404 (12) 334 (13) 70 (10) 0.044 64 (15) 0.068
Missing data 158 (4) 127 (4) 31 (4) 0.625 7 (2) 0.004
Days on dialysis before
active waitlisting, median (25–75th percentile)
253 (121–510) 246 (117–505) 282 (142–526) 0.023 291 (137–530) 0.099
The total study population consists of 3808 patients. Baseline characteristics are shown separately for patients remaining on dialysis during follow-up and those who were transplanted
during follow-up.
*P-value comparing patients remaining on dialysis versus transplanted patients. **P-valuecomparing SCD and ECD transplantation.
aAge at the moment when the patient was both actively waitlisted and on dialysis (whichever came second).
bAt the time of registration on the waiting list.
ADPKD, autosomal dominant polycystic kidney disease; TX, transplantation.
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hypertension/vascular disease. ECD recipients were less likely
to have ESRD because of glomerulonephritis or to have been
waitlisted before starting dialysis. Donor characteristics are
summarized in Supplementary data, File S1.
Time on the active waiting list and mortality during
waiting time
The median waiting time on the active waiting list for kidney
transplantation while on dialysis was significantly longer in the
younger age categories. In the youngest age group, the median
waiting time was 22.4 months (25th–75th percentiles 8.9–42.0);
in the middle age group, the median waiting time was
18 months (25th–75th percentiles 6.9–38.8) and in the oldest
age group, the median waiting time was 11.7 months (25th–
75th percentiles 3.6–28.7) (P< 0.0001 among all groups).
In the youngest age group, mortality during the median
waiting time (22 months) was 1.1% [95% confidence interval
(CI) 0.7–1.5]; in the middle age group, mortality during the me-
dian waiting time (18 months) was 2.3% (95% CI 1.7–2.9) and
in the oldest age group, mortality during the median waiting
time (12 months) was 2.5% (95% CI 1.6–3.3). There were only
minor differences in median waiting time between those who
eventually received an SCD versus ECD transplant within each
age group, with no substantial impact on mortality during the
median waiting time (Supplementary data File S2,).
Mortality during the median waiting time plus 3 years
post-transplantation or continued dialysis
In the youngest age group, when compared with those
remaining on dialysis, mortality was statistically significantly
lower for those transplanted with an SCD (Table 2 and Figure
2) and there was a clear trend towards a lower mortality for
those transplanted with an ECD.
In the middle age group, those transplanted with an ECD or
SCD had a statistically significantly lower mortality than those
remaining on dialysis. In addition, there was a clear trend to-
wards a lower mortality in those transplanted with an SCD
compared with those who received an ECD transplant.
In the oldest age group, mortality was statistically signifi-
cantly lower for those transplanted with an SCD than for those
remaining on dialysis. For those transplanted with an ECD, the
mortality tended to be lower than for patients remaining on di-
alysis, while it tended to be higher compared with patients who
received an SCD transplant.
Finally, we compared the relative mortality risk over time of
SCD and ECD transplantation with the mortality risk in
patients remaining on dialysis (Figure 3). In all age groups,
transplantation was associated with an increased risk of death
in the first months after transplantation but with a lower risk of
death later in the follow-up period. The mortality risk was con-
sistently higher with ECD than with SCD transplantation in all
age groups, with a peak at 3 months post-transplant.
Correspondingly, the period of increased mortality risk in
transplanted patients versus patients remaining on dialysis was
consistently longer for recipients of ECD kidneys than for SCD
kidney recipients: it was 7 versus 4 months for patients ages 20–
44 years, 18 versus 7 months for those ages 45–60 years and 26
versus 8 months in the65-year age group.
D I S C U S S I O N
We analysed long-term survival outcomes after kidney trans-
plantation versus dialysis in a cohort of Belgian patients on the
Eurotransplant waitlist. Our findings suggest that even patients
>65 years of age experience a survival benefit with transplanta-
tion, at least when transplanted with an SCD kidney. Outcomes
are less favourable when older patients are transplanted with an
ECD kidney. In fact, we did not observe a statistically significant
difference in survival between older patients receiving an ECD
transplantation and those remaining on dialysis, despite a trend
favouring ECD transplantation.
Our study showed that ECD transplantation in Belgium was
associated with a higher early post-transplant mortality risk




Mortality per 100 person years (%)

















FIGURE 2: Mortality during median waiting time (median waiting
time according to age group: age 20–44 years: 22 months; age
45–64 years: 18 months; age 65 years: 12 months) plus 3 years
post-transplantation or continued dialysis. Cox regression analysis
adjusted for age, sex, diabetes as the primary kidney disease (for
more details: see Methods section). *No overlap between 95% CIs.
Table 2. Mortality during the median waiting timea plus 3 years post-
transplantation or continued dialysis













Cox regression analysis adjusted for age, sex, primary renal disease.
a
Median waiting time according to age group: age 22–44 years: 22 months; age 45–64
years: 18 months; age 65 years: 12 months.
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findings [12]. This increased risk of early post-transplant mor-
tality with ECD versus SCD transplantation may result from an
increased risk for delayed or poor early graft function, which in
turn can lead to prolonged hospitalization. This situation gives
rise to difficulties with fluid and immunosuppressive drug man-
agement and with a higher risk for complications, such as infec-
tions and cardiovascular events, and for acute rejection [13–15].
Do these findings together mean that we should avoid trans-
planting older patients with ECD? This issue is complex. First,
the dichotomous classification of SCD versus ECD very much
oversimplifies the highly heterogeneous pool of donors. Some
ECD kidneys may lead to acceptable outcomes, while others
will do poorly [16]. A more granular score of donor quality,
such as the Kidney Donor Risk Index developed in the USA,
may be more appropriate [17]. More research is needed to as-
sess the added value of this index in estimating transplant out-
comes in Europe. Pre-implantation biopsies, as performed by
some transplant centres, could be another way to better assess
the quality of older-donor kidneys [18]. Second, although it
may be tempting to keep the patient on the waiting list until
there is an SCD donor offer, patients tend to accumulate
dialysis-related complications, which could lead to withdrawal
from the waitlist and a lost chance of ever getting transplanted.
In addition, even when they ultimately do receive an SCD trans-
plant, a longer dialysis period will remain a burden that may
negatively affect post-transplant survival [19, 20]. Finally, even
in the absence of a survival benefit, ECD transplantation could
lead to better physical, mental and social well-being compared
with dialysis, which may be the most important motivation for
choosing transplantation for older dialysis patients.
Other studies comparing outcomes with transplantation ver-
sus dialysis are limited and show somewhat contradictory
results. An analysis from a US population from the early 2000s
suggested a survival benefit with transplantation, even for recip-
ients >70 years of age and with ECDs [11]; however, the risks
vary with recipient comorbidities and donor type [12]. These
findings cannot be generalized to Europe, where survival out-
comes on dialysis and after transplantation appear to be better
than in the USA [21, 22]. Results of two European studies, from
France and Catalonia, also suggested a survival benefit with
transplantation, even in older recipients and even with the use
of ECDs [8, 9]. On the other hand, a recent analysis from the
Netherlands showed no survival benefit in patients>65 years of
age transplanted with kidneys from older donors [10].
It is difficult to interpret the diverging results of the studies,
not only because of the large heterogeneity between the popula-
tions, but also because of the varying methodology. It is obvi-
ously not possible to conduct a randomized trial to assess the
survival benefit of transplantation. The most appropriate ap-
proach is to compare outcomes of transplanted patients with
those of a control group of also waitlisted dialysis patients who
are not (yet) transplanted; these patient groups are most likely
to share common features. However, some selection bias will re-
main because healthier patients are somewhat more likely to be
transplanted than those who are less fit, because the latter tend
to have more complications and spend more time being tempo-
rarily considered ‘non-transplantable’. To minimize this bias,
we adjusted for age, sex and diabetes as the primary renal dis-
ease, but we lacked the data to adjust for comorbidities or for
time intervals spent being ‘non-transplantable’.
Selection of the appropriate starting point for analysing the
effect of transplantation on patient survival represents an addi-
tional methodological difficulty, often only vaguely addressed
in other studies [23]. Using the time of transplantation as the
starting point makes the starting point for those who are not
transplanted unclear. Thus, setting the start of dialysis for this
control group’s starting point would result in lead-time bias.
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A  Age ≥ 20–44
B  Age ≥ 45–64
C  Age ≥ 65
FIGURE 3: Adjusted relative risk of death over time after SCD or
ECD donor transplantation compared with patients remaining on
dialysis by age category. Adjusted relative mortality risk among 3382
recipients of a first deceased donor transplant compared with the ref-
erence group of 1852 patients still on dialysis after the median wait-
ing time (median waiting time according to age group: age 20–44
years: 22 months; age 45–64 years: 18 months; age 65 years:
12 months). Mortality rates are adjusted using fixed values for age,
sex and diabetes as cause of ESRD. Outcomes are shown separately
for recipients of an SCD and ECD. Dx, patients remaining on
dialysis.
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seems more appropriate. However, beginning from waitlisting
and then comparing outcomes between those who are trans-
planted and those remaining on dialysis would result in immor-
tal time bias for the transplanted group, as these patients will
survive until the day of kidney transplantation anyway. For this
reason, we decided to first calculate mortality during the me-
dian waiting time, with waiting time for both the transplanted
and non-transplanted patients based on a competing risk analy-
sis. We then added this result to the 3-year mortality risk after
transplantation and compared that outcome to an equal
amount of time (median waiting timeþ 3 years) in the dialysis
control group. Finally, we kept patients in the survival analysis
if they were delisted because of poor health status, because cen-
soring patients at delisting would have yielded an overestima-
tion of survival on dialysis.
We acknowledge that our methodology has several remain-
ing limitations. First, to maximize the power of our analyses, we
performed survival analyses on the total group rather than sepa-
rate analyses per age group. Then, age stratum–specific mortal-
ity rates were obtained by applying age stratum–specific fixed
values for age, sex and diabetes mellitus in the Cox regression
models. However, this approach uses the regression coefficients
for age, sex and diabetes mellitus that were based on the entire
sample and may therefore not entirely apply within the differ-
ent patient subgroups. Also, mortality may depend on other
factors that we have not adjusted for. Second, we chose to use
mortality during the median waiting time as an approximation
to overcome immortal time bias in the transplanted group.
However, in reality, waiting time and the corresponding mor-
tality during that waiting time differs between individuals.
Finally, in the analysis of survival, dialysis patients undergoing
dialysis who were censored at kidney transplantation may be
healthier and may therefore have better survival prospects com-
pared with those staying on dialysis, which may have resulted
in an overestimation of mortality on dialysis.
Other limitations of this study include the possibility of in-
complete registry data. It might be easier to keep track of
patients in a dialysis unit than those who are transplanted and
switch centres more easily, thus being more likely to be lost to
follow-up. Incomplete data carry the risk of underreporting
death with a functional graft, which also could have led to an
overestimation of the survival benefit of transplantation. The
sample size was relatively small, especially in the oldest age
group. Also, the dialysis control group diminished quickly as a
result of the high transplantation rate. These factors yielded sur-
vival estimates with relatively wide CIs and prevented a separate
analysis according to transplantation from either a donor after
brain death (DBD) or a donor after circulatory death (DCD). It
is not clear whether such a further differentiation would have
altered the conclusions. A recent analysis from the Netherlands
showed no difference in 5-year patient survival between those
receiving a DBD or a DCD transplant, even in patients
65 years of age receiving a kidney from a donor 65 years of
age [10]. Nevertheless, reports on differential long-term out-
comes with either DBD or DCD transplantation are conflicting
[24–26] and we believe stratifying the analysis according to
DBD or DCD donation would be desirable in a larger study.
Finally, the relatively short waiting times in Belgium may have
an impact on the prognosis after transplantation [19, 20] and
therefore the conclusions from our study may not be generaliz-
able to countries with much longer waiting times. Also, as the
survival benefit with transplantation continuously evolves due
to changes in dialysis and transplantation care, our study find-
ings may not be valid beyond the time period studied.
An important strength of this study is that it showed for the
first time in Belgium, the feasibility of linking national renal
registry data with that of a large transplant registry, such as
Eurotransplant. This achievement opens the possibility of
broadening the combined national registry/Eurotransplant
dataset to include other European countries and establishing
long-term scientific epidemiological collaborations involving
Eurotransplant and other transplant organizations to investi-
gate kidney transplantation in Europe. Furthermore, we aimed
for a transparent and detailed methodology description that
provides the opportunity for researchers to repeat the analyses
in other cohorts and directly compare outcomes among
cohorts.
In conclusion, the results of this study suggest that older
patients might gain a survival benefit with SCD transplantation
versus dialysis, but any survival benefit with ECD transplanta-
tion versus dialysis may be small. These findings should be
interpreted with caution and need to be re-evaluated and stud-
ied in more depth in a larger European cohort to provide more
precise estimates of the survival benefit with transplantation
and to enable a better prediction at the level of the individual
transplant candidate and his or her potential donor.
S U P P L E M E N T A R Y D A T A
Supplementary data are available at ndt online.
A C K N O W L E D G E M E N T S
The authors thank Gerda Van Beeumen, Sabine Verhofstede,
Els Meersman and Erik Snelders for administrative support.
F U N D I N G
R.H. received the 2018 ultra-short term ERA-EDTA
Fellowship award.
A U T H O R S ’ C O N T R I B U T I O N S
R.H., A.K., J.D.M., F.C., M.V.M., I.T., U.S., D.A., V.S. and K.J.
designed the study. R.H. and A.K. performed the analyses.
R.H., A.K., V.S., K.J. and D.A. interpreted the results. R.H.,
A.K. and V.S. wrote the manuscript. J.D.M. and F.C. provided
the data from the Belgian renal registries. D.K., M.J., S.V.L.,
A.L.M., J.M.K. and K.M.W. gave approval to use the data
from the Belgian transplant centres. K.L. contributed to the
data merging. M.V.M., E.D.V., I.T., S.V. and U.S. provided
the data from Eurotransplant. All authors reviewed and ap-
proved the manuscript before submission.






/ndt/advance-article/doi/10.1093/ndt/gfab024/6154301 by guest on 09 M
arch 2021
C O N F L I C T O F I N T E R E S T S T A T E M E N T
The authors of this manuscript have no conflicts of interest to
disclose.
D A T A A V A I L A B I L I T Y S T A T E M E N T
The data that support the findings of this study are available
from Eurotransplant and the Belgian registries (NBVN and
GNFB). Restrictions apply to the availability of these data,
which were used under license for this study. Data are avail-
able with the permission of Eurotransplant and the Belgian
registries (NBVN and GNFB).
R E F E R E N C E S
1. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all
patients on dialysis, patients on dialysis awaiting transplantation, and recipi-
ents of a first cadaveric transplant. N Engl J Med 1999; 341: 1725–1730
2. Eurotransplant International Foundation. Eurotransplant Annual Report
2016. http://www.eurotransplant.org/wp-content/uploads/2019/12/AR2016.
pdf
3. McAdams-Demarco MA, James N, Salter ML et al. Trends in kidney trans-
plant outcomes in older adults. J Am Geriatr Soc 2014; 62: 2235–2242
4. Port F, Bragg-Gresham J, Metzger R et al. Donor characteristics associated
with reduced graft survival: an approach to expanding the pool of kidney
donors. Transplantation 2002; 74: 1281–1286
5. Pascual J, Zamora J, Pirsch JD. A systematic review of kidney transplanta-
tion from expanded criteria donors. Am J Kidney Dis 2008; 52: 553–586
6. Kramer A, Stel V, Zoccali C et al. An update on renal replacement therapy
in Europe: ERA-EDTA registry data from 1997 to 2006. Nephrol Dial
Transplant 2009; 24: 3557–3566
7. United States Renal Data System. USRDS Annual Report 2018. https://
www.usrds.org/annual-data-report/previous-adrs/#tabname-1960-2
8. Savoye E, Tamarelle D, Chalem Y et al. Survival benefits of kidney trans-
plantation with expanded criteria deceased donors in patients aged 60 years
and over. Transplantation 2007; 84: 1618–1624
9. Lloveras J, Arcos E, Comas J et al. A paired survival analysis comparing he-
modialysis and kidney transplantation from deceased elderly donors older
than 65 years. Transplantation 2015; 99: 991–996
10. Peters-Sengers H, Berger SP, Heemskerk MBA et al. Stretching the limits of
renal transplantation in elderly recipients of grafts from elderly deceased
donors. J Am Soc Nephrol 2017; 28: 621–631
11. Rao PS, Merion RM, Ashby VB et al. Renal transplantation in elderly
patients older than 70 years of age: results from the Scientific Registry of
Transplant Recipients. Transplantation 2007; 83: 1069–1074
12. Gill JS, Schaeffner E, Chadban S et al. Quantification of the early risk of
death in elderly kidney transplant recipients. Am J Transplant 2013; 13:
427–432
13. Lee JR, Bang H, Dadhania D et al. Independent risk factors for urinary tract
infection and for subsequent bacteremia or acute cellular rejection.
Transplant J 2013; 96: 732–738
14. Yarlagadda SG, Coca SG, Formica RN et al. Association between delayed
graft function and allograft and patient survival: a systematic review and
meta-analysis. Nephrol Dial Transplant 2008; 24: 1039–1047
15. Tapiawala SN, Tinckam KJ, Cardella CJ et al. Delayed graft function and
the risk for death with a functioning graft. J Am Soc Nephrol 2010; 21:
153–161
16. Metzger RA, Delmonico FL, Feng S et al. Expanded criteria donors for kid-
ney transplantation. Am J Transplant 2003; 3(Suppl 4): 114–125
17. Rao PS, Schaubel DE, Guidinger MK et al. A comprehensive risk quantifica-
tion score for deceased donor kidneys: the kidney donor risk index.
Transplantation 2009; 88: 231–236
18. Gandolfini I, Buzio C, Zanelli P et al. The Kidney Donor Profile Index
(KDPI) of marginal donors allocated by standardized pretransplant donor
biopsy assessment: distribution and association with graft outcomes. Am J
Transplant 2014; 14: 2515–2525
19. Schold JD, Meier-Kriesche HU. Which renal transplant candidates should
accept marginal kidneys in exchange for a shorter waiting time on dialysis?
Clin J Am Soc Nephrol 2006; 1: 532–538
20. Haller MC, Kainz A, Baer H et al.Dialysis vintage and outcomes after kidney
transplantation: a retrospective cohort study. Clin J Am Soc Nephrol 2017;
12: 122–130
21. Goodkin DA, Young EW, Kurokawa K et al. Mortality among hemodialysis
patients in Europe, Japan, and the United States: case-mix effects. Am J
Kidney Dis 2004; 44: 16–21
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